amended pending claims are also listed below.

1. (Three Times Amended) A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 [:

a) an amino acid sequence of SEQ ID NO:1,

b) an amino acid sequence of SEQ ID NO:2

c) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody,

d) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody].

2. (Reiterated) A purified polypeptide selected from the group consisting of:

a) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:1 that binds specifically with an anti-PGAMP-1 antibody, and

b) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:2 that binds specifically with an anti-PGAMP-2 antibody.

14. (Reiterated) A purified antibody which specifically binds to a polypeptide of claim 1.

15. (Reiterated) A purified agonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

16. (Reiterated) A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

17. (Reiterated) A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

18. (Reiterated) A method for treating or preventing a reproductive disorder, the method

comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

21. (Reiterated) A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

22. (Reiterated) A composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.

23. (Reiterated) An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:3,

b) a polynucleotide sequence of SEQ ID NO:4,

c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,

d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4, and

e) a polynucleotide sequence complementary to a), b), c) or d).

24. (Reiterated) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising

hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and

detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

25. (Reiterated) A method of claim 24, wherein the probe comprises at least 30 contiguous nucleotides.

26. (Reiterated) A method of claim 24, wherein the probe comprises at least 60 contiguous nucleotides.

27. (Reiterated) A composition comprising a polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

Please add the following new claims:

28. (New) A substantially purified polypeptide comprising a fragment of the polypeptide of claim 1, wherein said fragment consists of at least 15 continguous amino acids of SEQ ID NO:1, and wherein said fragment binds specifically with an anti-PGAMP-1 antibody.

29. (New) A composition comprising the polypeptide of claim 28 in conjunction with a suitable pharmaceutical carrier.

30. (New) A method of screening for a compound that specifically binds to the polypeptide of claim 21, said method comprising the steps of:

a) combining the polypeptide of claim 21 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 21 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 21.

31. (New) A method for producing an antibody that specifically binds to the polypeptide of claim 21, the method comprising:

a) inoculating a mammal with the polypeptide of claim 21 under conditions such that the mammal makes antibodies that bind specifically to the polypeptide of claim 21, and

b) isolating said antibodies from said mammal.

32. (New) A method for determining whether a sample contains a polypeptide having the amino acid sequence of either SEQ ID NO:1 or SEQ ID NO:2, the method comprising: